Souhaitez-vous accéder aux communiqués récents ?

Total Revenues for Fiscal 2017 were $102.8 Million, up 33% Over Fiscal 2016; Exceeded Full-Year Revenue Guidance of $100 MillionFull-Year Proprietary Products Revenues up 42% Year-Over-Year Gross...

REHOVOT, Israel, Feb. 02, 2018 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that it will...

Kamada’s IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications Next...

Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed by Mount Sinai Acute GvHD International Consortium (MAGIC) to Identify Patients at High-Risk Kamada...

Three-Year Agreement Expected to Provide Revenues of Approximately $13 Million to Company Kamada’s Rabies Immune Globulin Recently Received FDA Approval REHOVOT, Israel, Nov. 21, 2017 (GLOBE...

Following Kamada’s Recent Withdrawal of European Marketing Authorization Application, Distribution Agreement Not Currently Warranted REHOVOT, Israel, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd....

Total Revenues for Third Quarter were $22.9 million, an 18% Increase Total revenues for first 9 months of 2017 were $67.1 million, a 26% Increase On Track to Achieve $100 Million in Total Revenues...

REHOVOT, Israel, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that the...

REHOVOT, Israel, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announced today that it will...

Efficacy trend was demonstrated in the pre-determined sub group of patients between the ages of 12 to 18, treated with the higher dose of 120mg/kg The positive trend was observed in this age group...